Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.

  • Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum.
  • ACHV has surged 173% over 52 weeks.
  • Shares recently hit a 3-year high earlier in July.
  • Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing its research pipeline.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.